{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-003293","form_type":"8-K","ticker":"CLSDQ","cik":"0001539029","company_name":"Clearside Biomedical, Inc.","filed_at":"2023-02-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.500934+00:00","generated_at":"2026-06-19T06:53:34.516191+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Clearside Biomedical CMO Thomas Ciulla resigns, becomes advisor under consulting agreement","bullets":["Thomas Ciulla resigned as CMO and CDO effective Feb 17, 2023; will serve as Chairman of Scientific Advisory Board and Chief Medical Advisor – Retina.","Consulting fee of $8,000 per month; initial term one year, renewable at Company's option.","Stock options continue vesting through Aug 31, 2023 (Jan 4, 2023 option through Jan 4, 2024); RSU vesting ceased on Feb 17, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-003293","json":"https://secwatch.observer/filing/0000950170-23-003293.json","markdown":"https://secwatch.observer/filing/0000950170-23-003293.md","text":"https://secwatch.observer/filing/0000950170-23-003293.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1539029/000095017023003293/0000950170-23-003293-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1539029/000095017023003293/clsd-20230217.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T06:53:34.516191+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"30c7061c7d","claim":"Thomas Ciulla resigned as Chief Medical Officer and Chief Development Officer at Clearside Biomedical, Inc..","evidence_excerpt":"Thomas Ciulla provided Clearside Biomedical, Inc. (the “ Company ”) notice of his resignation from his position as Chief Medical Officer and Chief Development Officer of the Company, with such resignation to be effective on February 17, 2023","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1539029/000095017023003293/0000950170-23-003293-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Medical Officer and Chief Development Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}